Back to Studies
P1110 / Safety and PK of RAL in Neonates
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1 Exposed Infants at High Risk
Clinical Trials Link
Primary Protocol Team Members
P1110 is a Phase I, open label, non-comparative dose-finding study of HIV-1 exposed full-term neonates (aged ≤48 hours) assessed as high risk of acquiring HIV-1 infection and their mothers. The study is designed to evaluate the safety and tolerability through 6 weeks of life of raltegravir oral granules for suspension when administered during the first 6 weeks of life with standard PMTCT ARV prophylaxis to HIV-1 exposed infants assessed at high risk of HIV infection.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...